Free Light Chains & Monoclonal Gammopathies
Impact on Diagnostic Panels
Back to Search Results
Test Utilization
Introduction
August 2008
Welcome to Mayo Medical Laboratories' Hot Topics. These presentations provide short discussion of current topics and may be helpful to you in your practice.
With the introduction of Mayo's expanded serum monoclonal protein panel, which includes quantitation of the kappa and lambda free light chains, urine monoclonal protein studies are no longer required as part of the initial diagnostic screen for monoclonal gammopathies.
Jerry Katzmann, PhD, from the Division of Clinical Biochemistry and Immunology at Mayo Clinic, discusses Mayo's approach to the diagnosis of monoclonal gammopathies and the use of serum free light chain assays.
Introduction |
Jump to section:
- Diagnostic Tests
- Mayo Clinic 1960-2003
- Plasma Cell Proliferative Disorders
- Serum Protein Electrophoresis & Immunofixation Electrophoresis
- Serum Protein Electrophoresis & Immunofixation Electrophoresis
- Monoclonal Serum Proteins: Newly Diagnosed Multiple Myeloma (n=1027)
- Serum Protein Electrophoresis & Immunofixation Electrophoresis
- Urine Protein Electrophoresis & Immunofixation Electrophoresis
- Intact Immunoglobulin/Free Light Chain
- FLC Reference Range
- Diagnoses for 428 Patients Selected for Urine Monoclonal Protein
- Serum PEL & IFE Results: 428 Pts with Urine Monoclonal Protein
- Laboratory Results: 428 Patients with Monoclonal Urinary Protein
- Potential Savings
- Uses of Serum Free Light Chain Assay
- Diagnostic Test Panel for Suspected Monoclonal Gammopathies
- Questions?
External
link
PDF
document
Excel
document
Word
document